Effects of Pegylated Glucagon-Like Peptide-1 Analogue in C57Bl/6 Mice under Optimal Conditions and During Streptozotocin-Induced Diabetes
- Authors: Skurikhin E.G.1, Stronin O.V.1, Epanchintsev A.A.1, Pershina O.V.1, Ermakova N.N.1, Krupin V.A.1, Pakhomova A.V.1, Vaizova O.E.2, Dygai A.M.1
-
Affiliations:
- Laboratory of Regenerative Pharmacology, E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Russian Academy of Sciences
- Department of Pharmacology, Siberian State Medical University, Ministry of Health of the Russian Federation
- Issue: Vol 163, No 5 (2017)
- Pages: 635-638
- Section: Article
- URL: https://journals.rcsi.science/0007-4888/article/view/239140
- DOI: https://doi.org/10.1007/s10517-017-3867-y
- ID: 239140
Cite item
Abstract
Biological activity of a new pegylated form of an of glucagon-like peptide-1 (GLP-1) analogue pegGLP-1 was studied in C57Bl/6 mice under normal conditions and during modeling of streptozotocin-induced type I diabetes mellitus. pegGLP-1 differs from GLP-1 (7-37) by polyethylene glycol residue covalently bound to His7, Lys26, and Lys34 of the GLP-1 molecule. It was shown that single intragastrical administration of pegGLP-1 induced an increase in GLP-1 level in blood serum of healthy mice. The maximum level of this parameter was observed in 4-8 h. pegGLP-1 elimination half-time was 8.5 h and mean retention time was 15 h. Administration of pegGLP-1 to animals with modeled type I diabetes mellitus was followed by an increase in the levels of GLP-1 and insulin in blood serum, produced a hypoglycemic effect, and improved the parameters of glucose-tolerance test. Biological activity of pegGLP-1 was higher than activity of GLP-1.
About the authors
E. G. Skurikhin
Laboratory of Regenerative Pharmacology, E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Russian Academy of Sciences
Author for correspondence.
Email: eskurihin@inbox.ru
Russian Federation, Tomsk
O. V. Stronin
Laboratory of Regenerative Pharmacology, E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Russian Academy of Sciences
Email: eskurihin@inbox.ru
Russian Federation, Tomsk
A. A. Epanchintsev
Laboratory of Regenerative Pharmacology, E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Russian Academy of Sciences
Email: eskurihin@inbox.ru
Russian Federation, Tomsk
O. V. Pershina
Laboratory of Regenerative Pharmacology, E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Russian Academy of Sciences
Email: eskurihin@inbox.ru
Russian Federation, Tomsk
N. N. Ermakova
Laboratory of Regenerative Pharmacology, E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Russian Academy of Sciences
Email: eskurihin@inbox.ru
Russian Federation, Tomsk
V. A. Krupin
Laboratory of Regenerative Pharmacology, E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Russian Academy of Sciences
Email: eskurihin@inbox.ru
Russian Federation, Tomsk
A. V. Pakhomova
Laboratory of Regenerative Pharmacology, E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Russian Academy of Sciences
Email: eskurihin@inbox.ru
Russian Federation, Tomsk
O. E. Vaizova
Department of Pharmacology, Siberian State Medical University, Ministry of Health of the Russian Federation
Email: eskurihin@inbox.ru
Russian Federation, Tomsk
A. M. Dygai
Laboratory of Regenerative Pharmacology, E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Russian Academy of Sciences
Email: eskurihin@inbox.ru
Russian Federation, Tomsk